60Degrees_logo_RGB_Logo.jpg
60 Degrees Pharma Announces IRB Approval of Clinical Study of Tafenoquine for Treatment of Babesiosis in Immunocompromised Patients with Persistent Babesia microti Despite Prior Treatment
July 09, 2024 06:31 ET | Sixty Degrees Pharmaceuticals
60 Degrees Pharma wins IRB approval for tafenoquine study for treating persistent babesiosis in immunocompromised patients despite prior treatment.
60Degrees_logo_RGB_Logo.jpg
60 Degrees Pharmaceuticals Funds Babesia spp Testing in Chronic Fatigue Patient Samples in NC State College of Veterinary Medicine Study
May 20, 2024 07:59 ET | Sixty Degrees Pharmaceuticals
60 Degrees Pharmaceuticals funds a study at NC State to test for Babesia spp in chronic fatigue patients, aiming to link these infections to CFS symptoms.